Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Accounts Payables: 2010-2024

Historic Accounts Payables for Heron Therapeutics (HRTX) over the last 12 years, with Dec 2024 value amounting to $11.7 million.

  • Heron Therapeutics' Accounts Payables rose 17.95% to $12.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.0 million, marking a year-over-year increase of 17.95%. This contributed to the annual value of $11.7 million for FY2024, which is 261.39% up from last year.
  • As of FY2024, Heron Therapeutics' Accounts Payables stood at $11.7 million, which was up 261.39% from $3.2 million recorded in FY2023.
  • In the past 5 years, Heron Therapeutics' Accounts Payables registered a high of $11.7 million during FY2024, and its lowest value of $525,000 during FY2020.
  • Moreover, its 3-year median value for Accounts Payables was $3.2 million (2023), whereas its average is $6.1 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first plummeted by 80.96% in 2020, then surged by 624.38% in 2021.
  • Heron Therapeutics' Accounts Payables (Yearly) stood at $525,000 in 2020, then spiked by 624.38% to $3.8 million in 2021, then decreased by 15.20% to $3.2 million in 2022, then increased by 0.47% to $3.2 million in 2023, then skyrocketed by 261.39% to $11.7 million in 2024.